tiprankstipranks
Trending News
More News >
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
US Market

Alnylam Pharma (ALNY) Income Statement

Compare
1,356 Followers

Alnylam Pharma Income Statement

Last quarter (Q3 2025), Alnylam Pharma's total revenue was $1.25B, an increase of 149.35% from the same quarter last year. In Q3, Alnylam Pharma's net income was $251.08M. See Alnylam Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 2.25B$ 1.83B$ 1.04B$ 844.29M$ 492.85M
Gross Profit
$ 1.92B$ 1.52B$ 868.60M$ 704.14M$ 414.80M
Operating Expenses
$ 2.10B$ 1.80B$ 1.65B$ 1.41B$ 1.24B
Depreciation and Amortization
$ 56.67M$ 54.05M$ 44.47M$ 47.57M$ 34.77M
EBITDA
$ -178.85M$ -258.24M$ -926.56M$ -661.56M$ -736.33M
Operating Income
$ -176.88M$ -282.18M$ -785.07M$ -708.65M$ -828.44M
Other Income/Expenses
$ -200.49M$ -151.34M$ -341.92M$ -143.49M$ -27.16M
Pretax Income
$ -377.38M$ -433.52M$ -1.13B$ -852.14M$ -855.60M
Net Income
$ -278.16M$ -440.24M$ -1.13B$ -852.82M$ -858.28M
Per Share Metrics
Basic EPS
$ -2.18$ -3.52$ -9.30$ -7.20$ -7.46
Diluted EPS
$ -2.18$ -3.52$ -9.30$ -7.20$ -7.46
Weighted Average Shares Outstanding
127.65M 124.91M 121.69M 118.45M 114.99M
Weighted Average Shares Outstanding (Diluted)
127.65M 124.91M 121.69M 118.45M 114.99M
Currency in USD

Alnylam Pharma Earnings and Revenue History